Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Breast Cancer Patient Congress Brought Scientists and Patients Together in an Important Social Responsibility Project! 2

The Breast Cancer Patient Congress Brought Scientists and Patients Together in an Important Social Responsibility Project! 2

The “Breast Cancer Patient Congress,” aiming to give patients direct access to current international cancer information, took place in Antalya on 28-29 June.

Reports containing information presented by our valued specialists will be published on our website in 5 parts. Follow them in the “cancer news” section.

Let us examine the second-day highlights in this series about this valuable congress raising breast cancer awareness..

Opening the second day, Memorial Health Group Antalya Oncology Group and Breast Diseases Association President Prof. Dr. Mustafa Özdoğan said: “We hope such congresses multiply and cover other cancers, bringing more correct information to more patients.”

First-panel moderator Prof. Dr. Nil Molinas Mandel, Medical Oncologist at the American Hospital, opened the session on early-stage surgery, lymphedema and follow-up.

“Whether breast-conserving surgery or mastectomy, whichever method is used, the breast is preserved, its shape unchanged, and years later the patient lives as though she never had breast surgery.”

First speaker University of Pittsburg breast surgeon Prof. Dr. Atilla Soran discussed innovations in early-stage cancer and surgery. He called breast cancer a social issue: “It seems more common in developed countries because inadequate screening elsewhere prevents accurate counts. Incidence is actually similar worldwide.” Underdeveloped countries detect less but have higher mortality, unlike developed countries. He emphasized that over the next 10 years American cancer deaths would exceed war deaths. In Türkiye, among 100.000 women, 38 develop breast cancer. Mortality is very low if caught early: “Do not lose hope. Early diagnosis means survival above %90-95; late detection greatly reduces it.”

He traced surgery from extensive removal in the 1800s to today's conservation. Recently in America, excessive tests and fear of recurrence have led women to remove healthy breasts too: “Without abnormalities in genes such as BRCA, removing a healthy breast does not prolong survival.”

“A technique used in America is the radioactive seed. Iodine 125 is inserted into a tumor too small to see during surgery. A detector locates it, and an instrument removes it through a small incision. The breast and underarm are checked to ensure clearance. Shape remains intact, and patients live for years as though surgery never happened.” Large tumors can also be reduced with neoadjuvant chemotherapy and then removed conservatively.

“Mastectomy removes the whole breast. Today we preserve skin and nipple, emptying the interior, then place an expander and silicone beneath the muscle so the patient retains her skin and nipple. If silicone is not preferred and the patient is overweight, abdominal muscle can be transferred toward the breast,” he explained of American methods.

“Whether conserving surgery or mastectomy, the breast and shape are preserved, and patients continue living years later as though no surgery occurred. All women should access fully equipped, quality-certified, skilled, comprehensive breast centers. I hope women in Türkiye can access similar centers and current evidence-based care.”

“Once postoperative chemotherapy benefits and tamoxifen's effectiveness were observed, postoperative chemotherapy and hormonal therapy became standard breast cancer treatments”

Second speaker Istanbul University Oncology Professor Dr. Yeşim Eralp discussed early-stage medical innovations, systemic treatment contributions and whether every treatment is available in Türkiye.

“A medical student's discovery that sterilizing sheep suppresses hormone secretion laid the foundations of today's highly effective hormonal treatment for sensitive breast tumors.” Tamoxifen, blocking estrogen's cancer effects, entered use in the 1970s. Once chemotherapy benefits were seen, early-stage effects were investigated. After surgery for nonmetastatic disease, these treatments increase life expectancy and reduce spread risk by approximately %20-50. “These benefits established postoperative chemotherapy and hormonal treatment as standard.”

Aromatase inhibitors, developed beyond tamoxifen and chemotherapy, block not only estrogen's tumor effects but hormone activity. They suppress estrogen produced in fat, tumor tissue and adrenal glands even after menopause, succeeding with tamoxifen or alone. “Not used before menopause, they can be made more effective by inducing menopause when needed.” Hormonal treatment is no longer limited to 5 years but extended to 8-10 to reduce recurrence.

She highlighted taxanes emerging after the 1980s, increasing treatment opportunity: “Chemotherapy contributes greatly, but the real research asks which patients and tumors need it.”

Genetic assessment and personalized treatment improve success. HER2 makes tumors more active. “After trastuzumab targeting HER 2 entered use, success increased, and in 2005 we began asking whether we were now successfully beating breast cancer.”

Research continues into underlying genetic changes and increasing host immune responses. Appropriate treatment must be determined by a well-functioning multidisciplinary team.

She said drug access is not problematic: “All drugs are reimbursed in Türkiye; when another is needed, we submit an off-label application.” Systemic treatment reduces mortality by %30. Goals are spreading early diagnosis through awareness and achieving correct, current treatment, with equal quality for all patients in the future.

“Shorter radiotherapy courses will begin soon. Most importantly, early diagnosis allows very small treatment areas and very minor side effects while overcoming this disease.”

Third speaker, Memorial Health Group Antalya Radiation Oncology Associate Professor Dr. Berrin Pehlivan, discussed innovations in early-stage breast radiotherapy.

Radiotherapy is a main treatment step: “With surgical advances, we now irradiate almost all patients.” Its aim is less normal-tissue damage, less recurrence and longer survival. Over the last 20 years it has changed alongside surgery, with technology allowing smaller areas and fewer side effects. Omitting it after breast-conserving surgery instead of mastectomy increases recurrence risk by %40. She described 3-dimensional, intensity-modulated and brachytherapy approaches, with continually developing methods.

She discussed partial radiotherapy targeting only the tumor area. “Breathing moves organs, making targeting difficult; intense radiation may miss and harm normal tissue. Image-guided treatment compares and matches images at each session.” Imaging also monitors and updates treatment. Respiratory-gated radiotherapy protects the heart when treating the nearby breast.

Standard courses last 5-7 weeks, while suitable distant-traveling patients can receive partial treatment completed in 1-5 days. This short, intense approach is limited to selected cases. Recurrences after conservation usually occur in or near the tumor bed, supporting partial treatment. “We can use it above age 60, with a single tumor smaller than 2 cm, negative nodes and adequate surgical margins. However, intense short treatment can increase side effects in elderly heart and diabetes patients.”

Quality of life matters as much as diagnosis and treatment: “Shorter courses are coming, but early diagnosis allows tiny areas and minor effects. Please value early diagnosis and trust us a little.”

“From diagnosis, think of living with and beyond cancer. Breast cancer is not yours alone; it concerns family, surroundings and society.”

The panel's final speaker, University of Pittsburg Prof. Dr. Barry Lembersky, explained follow-up after early-stage treatment.

He called breast cancer a major global problem, accounting for %23 of women's cancers, increasing in Türkiye and worldwide and a major cause of death. Türkiye now also offers early diagnosis and treatment.

“In America in 2013, breast cancer cases numbered 230.000. Lung cancer is the leading female cancer killer, breast cancer second. In 2013, 40.000 women died of breast cancer. Mortality nevertheless declines in both countries.”

Follow-up, like early diagnosis, must be individualized. Doctors should consider life after treatment from the first diagnostic day: “Think of living with and beyond cancer; it involves family and society too.”

American follow-up programs must be evidence-based and are increasing. “Follow-up begins early. Transitional follow-up covers the first post-treatment year; long-term follow-up spans 1-5 years. Recurrence may occur during these 1-5 years, beginning another period of living with cancer. Persistent disease requires permanent follow-up. We hope to consider it gone after 5 years.”

“Clinics and programs must help people living after treatment”

A survey in America in 2010 found recurrence fear was patients' greatest concern. Depression, family loss, changed appearance, low energy, poor concentration and sexual problems also worried them. Clinics and programs should support survivors.

His patients' main question after treatment is “What now?” He begins by explaining that %80-90 recover and that surgery, chemotherapy and radiotherapy all contribute to survival.

He explains recurrence from pathology and tumor biology: “For the worst, triple (3)-negative tumors, recurrence may occur in the first 3-4 years; estrogen receptor-positive tumors rarely recur early but may very rarely appear after 10-15 years. That is the bad news; the good news is that %80-90 will not have breast cancer again.”

Recurrence fear is important in the first 5 years in both countries. He follows a simple American Breast Cancer Organization guide: “For the first 3 years, history and examination every 3-6 months; between 3-5 years, every 6 months; then annually. Report breathlessness, pain or other complaints. Mammography begins 1 year after diagnosis, then annually. Family history always prompts genetic consultation.”

He collaborates with surgery, radiation therapy and family medicine, screening for other cancers such as bowel and ovarian. In asymptomatic early-stage breast cancer, however, blood tests, tumor markers, PET, CT, bone scintigraphy, chest X-ray and MRI are not routinely used: false positives may lead to unnecessary extra testing.

He recommends exercise and yoga for quality of life and reduced anxiety. Chemobrain memory problems prompt psychiatric referral. For dryness, discharge and sexual withdrawal, solutions include vaginal estrogen creams, which he said do not trigger cancer, and sex therapy, available in Türkiye. Acupuncture may help hot flashes and insomnia. For muscle and joint pain, medication is stopped for 4-6 weeks, a “drug holiday,” changed or replaced with tamoxifen. Bone-protective drugs and calcium are given. Aromatase inhibitor users receive DEXA annually or every 2 years.

Weight control matters because excess weight can trigger recurrence; a nutrition specialist should prepare appropriate food plans. Follow-up is an increasing challenge, addressed in America through clinics bringing together doctors, psychologists, nutrition specialists and patient rights.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Breast Cancer Patient Congress Brought Scientists and Patients Together in an Important Social Responsibility Project! 2

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy